NPM1 and acute myeloid leukemia: The WT1 mutation appears to be more prevalent among patients diagnosed with AML with CEBPA-bZIP or double CEBPA mutation, and the concurrence of WT1 mutation could worsen the prognosis of some favorable-risk subsets, such as AML with NPM1 and AML associated with CEBPA-bZIP mutation [19].